Viridian Therapeutics (VRDN): Stifel Sees 198% Price Potential - Convincing Long-Term Data From the Phase 3 Study THRIVE!
Reading Time: 3 minutes
Viridian Therapeutics (VRDN) announced positive long-term data from the Phase 3 study THRIVE on May 20, 2025, which investigated the drug Veligrotug in patients with active thyroid eye disease (TED). The study showed that 70% of patients who achieved a significant reduction in exophthalmos (proptosis) after 15 weeks maintained this treatment success even after 52 weeks. The definition of treatment success was based on a reduction of at least 2 millimeters compared to baseline, without worsening in the other eye. Additionally, the safety profile...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
